Whole blood and serum for immunologic assays. 6.3 Timing and Evaluation 6.3.1 Informed Consent Study personnel will meet with prospectiv e study subjects , explain the study, and provide them with an informed consent form (ICF) that describes the screening tests, eligibility criteria for entering the study, and study treatments and follow -up procedures. The subjects must sign the ICF before the study can commence. 6.3.2 Assignment of Subject Numbers Study personnel will screen subjects and assign allocat ion numbers as appropriate. Each subject who consents will be assigned a patient identification number (PI N) which identifies the subject for all s tudy- related procedures for the duration of their participation in the study. Once assigned, PINs cannot be reused for any reason 6.3.3 Medical History/Existing Events/Illnesses Investigators should document all relevant and clinically significant non- cancer rel ated illnesses that the subject has experienced within 5 years prior to screening and all prior cancer related illnesses as Medical History. The determination of the relevance includes, but not limited to, the history related to HNSCCa and treatment for HN SCCa, major surgery and procedures, on -going medical conditions that require continuous treatment or close follow up/monitoring, history of hypersensitivity and allergic events. Illnesses’ first occurring or detected after the ICF is signed or during the study and/or worsening of an existing illness during the study are to be documented as AEs on the CRF. Prior treatments, defined as administered prior to first immunotherapy treatment, should be recorded in the CRF as prior medications. Concomitant treatme nts, defined as treatments continued by the subject upon entry into the study and new treatments taken after the first immunotherapy treatment, should be recorded in the CRF as concomitant medications. The subject’s previous anti -cancer treatments, includi ng detailed information about their therapy directed against HNSCCa (e.g. past surgical and/or radiation regimens) should be documented. Additionally, information about any non-cancer treatments should also be noted. 6.3.4 Safety Assessments The following subjec t evaluations for safety will be performed. 40 Date: 8 April 2016 v 2.1 INO-3112 UPCC # 39313 / Inovio HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol 6.3.4.1 Participant Reminder Card Subjects record any post treatment reactions and enter this information on the participant reminder card. The study staff will review the reminder card and assess the reported events for clinical significance. Study staff should evaluate each unique reminder card entry according to CTCAE guidelines (Version 4.03) and Table 6.1 of the protocol, “Grading Scale for Injection Site Reactions.” Any reminder card entry determined to meet the c riteria for a Grade 1 or higher adverse event should be documented as an adverse event unless deemed part of the subject’s ongoing medical history. If the reminder card entry does not meet the criteria of a Grade 1 or higher AE as per the CTCAE guidelines, clinical judgment can be used to determine whether the entry should be recorded as an AE and documented accordingly in the site’s source . For cases where the reminder card entry and final AE reporting (i.e. grading) do not agree, the reasoning should be r ecorded in the source documents. 6.3.4.2 Medical/Clinical Assessments and concomitant medications New onset disease and concomitant medications will be queried from the f irst time reported through to the end of study visit/discharge. Assessment of adverse events will be collected from the time of informed consent through End of Study visit and will be assessed using the “Common Terminology Criteria for Adverse Events (CTCAE)”, version 4.03 issued by the US Department of Health and Human S ervices on June 14, 2010. 6.3.4.3 Physical Assessments A complete physical examination will be conducted at specified visits. A targeted physical assessment will be performed at other visit as determined by the Investigator or directed per subject complaints. The injection site is to be as sessed by the study personnel within 30 – 45 minutes after EP, and during subsequent clinic visits as specified in the schedule of events (Tables S1 and S2 ). 6.3.4.4 Vital Signs Vital signs may include but are not limited to, body temperature, oxygen saturation, blood pressure and heart rate will be measured at specified visits. 6.3.4.5 Weight and Height Weight (kg) and height (cm) will be collected at specified visits. The information can be used for body mass index (BMI) calculations. 6.3.4.6 12-Lead ECGs An ECG will be perfor med within 28 days of the first dose of immunotherapy for eligibility . 6.3.4.7 Pregnancy Test Women of reproductive potential must have a negative serum β- HCG test at screening and a negative serum or urine (with sensitivity of at least 25 mIU/mL) β -HCG within 72 hours prior to administration of immunotherapy. If at any point the β -HCG test is positive, indicating that the subject is pregnant, no additional immunotherapy will be administered, but the subject will be followed for the duration of the study and beyond to determine the outcome of the pregnancy (with the subject’s consent). 41 Date: 8 April 2016 v 2.1 INO-3112 UPCC # 39313 / Inovio HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol 6.3.4.8 Eastern Cooperative Oncology Group (ECOG) ECOG performance status will be measured at specified visits. 6.3.4.9 Laboratory Evaluations Blood samples will be taken to be tested for serum chemistry and complete blood count as specified in the Schedule of Events (Tables S1 and S2). Complete Blood Count White blood cell (WBC) count with differential, Red blood cell (RBC) count, Hemoglobin, Hematocrit, Platelet count and PT, INR/PTT (screening only). Serum Chemistry Bilirubin, alkaline phosphatase, SGPT (serum glutamic -pyruvic transaminase)/ALT, SGOT (serum glutamic -oxaloacetic transaminase)/AST, creatinine, electrolytes, calcium, albumin and CPK ( at screening and at 2 weeks after the last dose of immunotherapy only ). Serology (screening only): Antibody to human immunodeficiency virus (HIV -Ab), hepatitis B surface antigen (HBsAg), antibody to hepatitis C virus (HCV) 6.4 Optional c ollection of Leftover Tumor Tissue Sample Leftover tumor tissue samples may be collected through subject’s standard of care during the course of the study . The tumor tissue samples will be used for immunological and correlative assessments. 6.5 HLA Testing HLA testing will be performed on PBMC from any single blood sample collec ted for immunogenicity analysis after screening visit. If the subject has a record of previous high resolution HLA testing and access to results, this HLA testing is not required. The DNA extracted from the blood sample will be used to determine if allel es at the MHC locus affect the immune response to study treatment. Data arising from this study will be subject to same confidentiality as the rest of the study.